Sanofi and CD&R close Opella transaction, creat

赛诺菲和CD&R完成Opella交易，创建

e

e

global consumer healthcare leader

全球消费者医疗保健领域的领导者

Paris, April 30, 2025

巴黎，2025年4月30日

.

。

Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake.

今天，奥佩拉成为消费者健康领域的独立全球领导者，标志着赛诺菲战略的关键一步。赛诺菲今天宣布，已向CD&R出售其消费者健康业务奥佩拉50.0%的控股权。赛诺菲仍持有奥佩拉48.2%的重要股份。

Bpifrance will own a 1.8% stake in Opella and will join the Board. The transaction was completed on the terms previously disclosed. Sanofi has received total net cash proceeds of around €10 billion. .

法国公共投资银行将持有奥佩拉1.8%的股份，并将加入董事会。该交易按照之前披露的条款完成。赛诺菲已获得约100亿欧元的总净现金收益。

Sanofi is now a pure-play biopharma, strategically focused on pushing the boundaries of science and leveraging cutting-edge research to deliver breakthrough medicines and vaccines.

赛诺菲现在是一家专注于生物制药的公司，战略上专注于推动科学的边界，并利用尖端研究提供突破性的药物和疫苗。

Paul Hudson

保罗·哈德逊

Chief Executive Officer, Sanofi

赛诺菲首席执行官

“We have full confidence in Opella’s future as a new independent champion. Built on the strength of its talented teams, deep consumer understanding, and international reach, Opella is perfectly positioned for long-term success. With the support of CD&R—renowned for its expertise in the consumer and healthcare sectors and its commitment to people, communities, and sustainability, Opella is ready to grow and thrive.

“我们对Opella作为一家全新独立领军企业的未来充满信心。凭借其才华横溢的团队、深厚的消费者洞察力以及国际化的布局，Opella已经为长期成功奠定了坚实的基础。在CD&R的支持下——这家以消费者和医疗保健领域专业能力著称，并致力于员工、社区和可持续发展的机构，Opella已准备好实现成长与繁荣。

This new chapter marks the beginning of a promising journey for a company we believe in deeply.” .

这一新篇章标志着我们深信不疑的一家公司充满希望的旅程的开始。

Eric Rouzier

埃里克·鲁齐尔

Partner and Head of European Healthcare, CD&R

欧洲医疗保健合伙人兼负责人，CD&R

“This is an exciting opportunity for CD&R to support Opella in building a French headquartered, global consumer health champion. Opella stands out through the strength of its brands and the expertise of its people. CD&R brings complementary experience in the consumer health sector, along with operational insight and long-term capital, to help accelerate Opella’s growth.

“这对于CD&R来说是一个令人兴奋的机会，可以支持Opella打造一家总部位于法国的全球消费者健康领军企业。Opella凭借其品牌的实力和员工的专业知识脱颖而出。CD&R带来了在消费者健康领域的互补经验、运营洞察力以及长期资本，以帮助加速Opella的增长。”

We are committed to supporting Opella’s continued development, both in France and abroad and to better serving employees, consumers, and patients alike.”.

我们致力于支持奥佩拉在法国和国外的持续发展，并更好地服务员工、消费者和患者。

Julie Van Ongevalle

朱莉·范·昂格瓦勒

President and Chief Executive Officer, Opella

奥佩拉总裁兼首席执行官

“Reaching this milestone is an exciting moment in Opella's journey. Through significant transformations, we have become one of the largest global players in our sector, bringing innovation to over half a billion consumers worldwide. We are ready to unlock Opella’s full potential, drive value creation, and leverage our teams' exceptional talent to become a leader in the fast-moving consumer healthcare space.”.

“达成这一里程碑是欧佩拉历程中的激动人心的时刻。通过重大的转型，我们已经成为本行业中全球最大的参与者之一，为全球超过五亿消费者带来创新。我们已准备好充分释放欧佩拉的潜力，推动价值创造，并利用我们团队的卓越才能，成为快速消费品医疗保健领域的领导者。”

Headquartered in France, Opella employs over 11,000 talented and passionate people, operates in 100 countries with 13 best-in-class and strategic manufacturing sites and four science and innovation development centers. With a portfolio of iconic brands, such as Allegra, Doliprane, and Dulcolax, Opella is already the third-largest business worldwide in the over-the-counter and vitamins, minerals & supplements market (OTC & VMS), serving more than half a billion consumers worldwide.

总部位于法国，Opella 拥有超过 11,000 名才华横溢且充满热情的员工，在 100 个国家开展业务，拥有 13 个一流的战略制造基地和四个科学与创新研发中心。凭借 Allegra、Doliprane 和 Dulcolax 等标志性品牌，Opella 已成为全球第三大非处方药及维生素、矿物质和补充剂市场（OTC 和 VMS）企业，为全球超过 5 亿消费者提供服务。

Opella operates in a fast-growing industry driven by sustainable long-term trends, such as an aging population, rising income levels, and greater health and well-being awareness..

奥佩拉所在的行业受可持续的长期趋势推动，发展迅速，这些趋势包括人口老龄化、收入水平上升以及健康意识和幸福感增强。

About Sanofi

关于赛诺菲

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

我们是一家创新的全球医疗保健公司，由一个目标驱动：我们追求科学的奇迹以改善人们的生活。我们的团队遍布全球，致力于通过努力将不可能变为可能来改变医学实践。我们为全球数百万人提供可能改变生命的治疗选择和挽救生命的疫苗保护，同时将可持续发展和社会责任置于我们雄心的中心。

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY..

赛诺菲在 EURONEXT：SAN 和 NASDAQ：SNY 上市。

Media Relations

媒体关系

Sandrine Guendoul

桑德琳·根杜尔

| +33 6 25 09 14 25 |

| +33 6 25 09 14 25 |

sandrine.guendoul@sanofi.com

桑德琳·根杜尔@赛诺菲.com

Victor Rouault

维克多·鲁奥

| +33 6 70 93 71 40 |

| +33 6 70 93 71 40 |

victor.rouault@sanofi.com

victor.rouault@sanofi.com

Léo Le Bourhis

莱奥·勒布尔希斯

| +33 6 75 06 43 81 |

| +33 6 75 06 43 81 |

leo.lebourhis@sanofi.com

leo.lebourhis@sanofi.com

Léa Ubaldi

莱娅·乌巴尔迪

| +33 6 30 19 66 46 |

| +33 6 30 19 66 46 |

lea.ubaldi@sanofi.com

lea.ubaldi@sanofi.com

Evan Berland

埃文·贝兰德

| +1 215 432 0234 |

| +1 215 432 0234 |

evan.berland@sanofi.com

evan.berland@赛诺菲.com

Timothy Gilbert

蒂莫西·吉尔伯特

| +1 516 521 2929 |

| +1 516 521 2929 |

timothy.gilbert@sanofi.com

timothy.gilbert@sanofi.com

Investor Relations

投资者关系

Thomas Kudsk Larsen

托马斯·库兹克·拉森

| +44 7545 513 693 |

| +44 7545 513 693 |

thomas.larsen@sanofi.com

thomas.larsen@sanofi.com

Alizé Kaisserian

阿里泽·凯塞里安

| +33 6 47 04 12 11 |

| +33 6 47 04 12 11 |

alize.kaisserian@sanofi.com

alize.kaisserian@sanofi.com

Felix Lauscher

费利克斯·劳舍尔

| +1 908 612 7239 |

| +1 908 612 7239 |

felix.lauscher@sanofi.com

felix.lauscher@sanofi.com

Keita Browne

凯塔·布朗

| +1 781 249 1766 |

| +1 781 249 1766 |

keita.browne@sanofi.com

keita.browne@sanofi.com

Nathalie Pham

纳塔莉·范

| +33 7 85 93 30 17 |

| +33 7 85 93 30 17 |

nathalie.pham@sanofi.com

纳塔莉·法姆@赛诺菲.com

Tarik Elgoutni

塔里克·埃尔戈特尼

| +1 617 710 3587 |

| +1 617 710 3587 |

tarik.elgoutni@sanofi.com

塔里克·埃尔古蒂@赛诺菲.com

Thibaud Châtelet

蒂博·沙特莱

| +33 6 80 80 89 90 |

| +33 6 80 80 89 90 |

thibaud.chatelet@sanofi.com

thibaud.chatelet@sanofi.com

Yun Li

李云

| +33 6 84 00 90 72 |

| +33 6 84 00 90 72 |

yun.li3@sanofi.com

yun.li3@sanofi.com

Forward-looking statements

前瞻性声明

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, business transformations, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance.

本新闻稿包含根据1995年《私人证券诉讼改革法案》（经修订）定义的前瞻性陈述。前瞻性陈述并非历史事实。这些陈述包括预测、估计及其基本假设，关于计划、业务转型、目标、意图和对未来财务结果、事件、运营、服务、产品开发及潜力的预期，以及关于未来表现的陈述。

Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “potential”, “outlook”, “guidance” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements.

前瞻性陈述通常通过“预期”、“预计”、“相信”、“意图”、“估计”、“计划”、“潜力”、“展望”、“指引”以及类似表述加以识别。尽管赛诺菲的管理层认为这些前瞻性陈述中反映的预期是合理的，但投资者应注意，前瞻性信息和陈述受到各种风险和不确定性的影响，其中许多难以预测且通常超出赛诺菲的控制范围，可能导致实际结果和发展与前瞻性信息和陈述中表达或暗示或预测的内容存在重大差异。

These risks and uncertainties include among other things, those inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and com.

这些风险和不确定性包括但不限于研发、未来临床数据及分析（包括上市后）、监管机构（如FDA或EMA）的决定，涉及是否以及何时批准任何药物、设备或生物制品申请，及其关于标签和其他可能影响此类候选产品可用性或商业潜力的事项的决定，候选产品即使获得批准也可能无法取得商业成功，未来审批和商业化等。

All trademarks mentioned in this press release are the property of the Opella group.

本新闻稿中提到的所有商标均为Opella集团的财产。

Attachment

附件

Press_Release

新闻稿

Share

分享